Abbott Laboratories (ABT) Expected to Announce Quarterly Earnings on Thursday

Abbott Laboratories (NYSE:ABT) is expected to be releasing its Q2 2026 results before the market opens on Thursday, July 16th. Analysts expect Abbott Laboratories to post earnings of $1.28 per share and revenue of $12.5184 billion for the quarter. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 16, 2026 at 9:00 AM ET.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the company posted $1.09 earnings per share. On average, analysts expect Abbott Laboratories to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Abbott Laboratories Price Performance

NYSE:ABT opened at $95.12 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a fifty day moving average price of $89.15 and a 200 day moving average price of $103.53. The stock has a market cap of $165.68 billion, a P/E ratio of 26.64, a PEG ratio of 1.65 and a beta of 0.61.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. Abbott Laboratories’s payout ratio is presently 70.59%.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction dated Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 0.46% of the company’s stock.

Institutional Trading of Abbott Laboratories

Large investors have recently bought and sold shares of the stock. Brighton Jones LLC increased its holdings in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Pinnacle Financial Partners Inc. lifted its holdings in Abbott Laboratories by 21.0% during the 3rd quarter. Pinnacle Financial Partners Inc. now owns 122,698 shares of the healthcare product maker’s stock worth $16,434,000 after buying an additional 21,301 shares in the last quarter. Sivia Capital Partners LLC raised its position in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after acquiring an additional 162 shares during the last quarter. United Bank increased its position in Abbott Laboratories by 7.4% in the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after purchasing an additional 2,001 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $85,000. 75.18% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on ABT. Robert W. Baird started coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective for the company. TD Cowen lowered their price target on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. Jefferies Financial Group reduced their price objective on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Bank of America lowered their price objective on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $118.42.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.